S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
T   39.63 (+0.33%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
T   39.63 (+0.33%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
T   39.63 (+0.33%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
T   39.63 (+0.33%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
DIS   147.65 (+2.06%)
Log in

AxoGen Stock Price, Forecast & Analysis (NASDAQ:AXGN)

$15.59
-0.61 (-3.77 %)
(As of 11/18/2019 04:00 PM ET)
Today's Range
$15.59
Now: $15.59
$16.42
50-Day Range
$11.29
MA: $12.74
$16.10
52-Week Range
$10.91
Now: $15.59
$35.11
Volume36,833 shs
Average Volume488,298 shs
Market Capitalization$615.34 million
P/E RatioN/A
Dividend YieldN/A
Beta0.14
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXGN
CUSIPN/A
Phone386-462-6800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$83.94 million
Book Value$3.43 per share

Profitability

Net Income$-22,400,000.00

Miscellaneous

EmployeesN/A
Market Cap$615.34 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive AXGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.


AxoGen (NASDAQ:AXGN) Frequently Asked Questions

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

How were AxoGen's earnings last quarter?

AxoGen, Inc (NASDAQ:AXGN) posted its quarterly earnings data on Monday, October, 29th. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The medical equipment provider had revenue of $22.66 million for the quarter, compared to the consensus estimate of $22.52 million. AxoGen had a negative return on equity of 17.82% and a negative net margin of 26.79%. The business's revenue for the quarter was up 41.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.04) EPS. View AxoGen's Earnings History.

When is AxoGen's next earnings date?

AxoGen is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for AxoGen.

What price target have analysts set for AXGN?

5 equities research analysts have issued 1-year target prices for AxoGen's shares. Their forecasts range from $19.00 to $28.00. On average, they expect AxoGen's share price to reach $23.25 in the next year. This suggests a possible upside of 49.1% from the stock's current price. View Analyst Price Targets for AxoGen.

What is the consensus analysts' recommendation for AxoGen?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AxoGen.

What are Wall Street analysts saying about AxoGen stock?

Here are some recent quotes from research analysts about AxoGen stock:
  • 1. BTIG Research analysts commented, "Raise PT to $29 We reiterate our Buy rating and raise our price target to $29 (from $28) following 1Q19 results. 1Q19 results beat both BTIG and Consensus est. with rev. of $23.3M (+34.9% Y/Y) coming in ahead of (~29% implied). Expenses were elevated as one-timers, increasing sales reps, and costs associated with RECON stepped up, but mgmt. expects these costs to moderate through the year. When we upgraded AXGN intra-quarter (here), the crux of our thesis was that improved stability and hiring trends in the sales force following the leadership transition would lead to more consistent execution and allow AXGN to return to improved growth. Thus far, results are playing out as we surmised but we acknowledge it’s still early in the year." (5/10/2019)
  • 2. Cantor Fitzgerald analysts commented, "We think AXGN is one of the most compelling growth stories in medtech, with what we believe is sustainable top-line growth of north of 30% for the next two years. We expect utilization to accelerate as favorable clinical and economic data builds and increases surgeon awareness. We would also expect the company to continue to pursue additional market opportunities, as the technology is applicable to nerves across the body. Valuation Summary We value AXGN using a 6x EV/Sales multiple on our 2020 sales estimate to arrive at our 12-month price target of $26." (1/18/2019)

Has AxoGen been receiving favorable news coverage?

Media coverage about AXGN stock has been trending very negative recently, according to InfoTrie. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AxoGen earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media stories about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for AxoGen.

Are investors shorting AxoGen?

AxoGen saw a decrease in short interest in the month of October. As of October 31st, there was short interest totalling 1,510,000 shares, a decrease of 11.7% from the September 30th total of 1,710,000 shares. Based on an average daily volume of 451,100 shares, the short-interest ratio is currently 3.3 days. Approximately 4.2% of the company's shares are sold short. View AxoGen's Current Options Chain.

Who are some of AxoGen's key competitors?

What other stocks do shareholders of AxoGen own?

Who are AxoGen's key executives?

AxoGen's management team includes the folowing people:
  • Ms. Karen Zaderej, Chairman, Pres & CEO (Age 57)
  • Mr. Peter J. Mariani, Chief Financial Officer (Age 55)
  • Mr. Gregory G. Freitag Esq., J.D., CPA, Gen. Counsel & Director (Age 57)
  • Mr. Michael Donovan, VP of Operations (Age 54)
  • Ms. Kaila Paige Krum, VP of Investor Relations & Corp. Devel.

Who are AxoGen's major shareholders?

AxoGen's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (1.63%), Perkins Capital Management Inc. (0.81%), Pennsylvania Trust Co (0.53%), State of New Jersey Common Pension Fund D (0.29%), California Public Employees Retirement System (0.17%) and Granite Point Capital Management L.P. (0.13%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Daniel Pietrzak, David K Hansen, Gregory Gene Freitag, Guido J Neels, Isabelle Billet, Jamie Mark Grooms, Karen L Zaderej, Michael Patrick Donovan, Quentin S Blackford and Shawn F Mccarrey. View Institutional Ownership Trends for AxoGen.

Which institutional investors are selling AxoGen stock?

AXGN stock was sold by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P. and Perkins Capital Management Inc.. Company insiders that have sold AxoGen company stock in the last year include David K Hansen, Gregory Gene Freitag and Michael Patrick Donovan. View Insider Buying and Selling for AxoGen.

Which institutional investors are buying AxoGen stock?

AXGN stock was acquired by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Gabelli Funds LLC, Pennsylvania Trust Co, Russell Investments Group Ltd., Peregrine Capital Management LLC, California Public Employees Retirement System, Synovus Financial Corp and Parallel Advisors LLC. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, Daniel Pietrzak, Isabelle Billet, Karen L Zaderej and Quentin S Blackford. View Insider Buying and Selling for AxoGen.

How do I buy shares of AxoGen?

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $15.59.

How big of a company is AxoGen?

AxoGen has a market capitalization of $615.34 million and generates $83.94 million in revenue each year. The medical equipment provider earns $-22,400,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. View Additional Information About AxoGen.

What is AxoGen's official website?

The official website for AxoGen is http://www.axogeninc.com/.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]


MarketBeat Community Rating for AxoGen (NASDAQ AXGN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  382 (Vote Outperform)
Underperform Votes:  267 (Vote Underperform)
Total Votes:  649
MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote "Outperform" if you believe AXGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel